BACKGROUND: The Ontario Blood Pressure (ON-BP) survey reported high treatment and control rates for hypertension in the province of Ontario, Canada, in a survey performed in 2006. This study examined patterns of utilization of antihypertensive drug classes and their impact on blood pressure (BP) control. METHODS: Cross-sectional, population-based survey of adults, 20-79 years of age (population 7,996,653). Responses are weighted to the Ontario hypertensive population of 1,498,045. RESULTS: Of all hypertensives, 51 and 49% were on monotherapy vs. 2+ drug therapy with similar control rates (86 vs. 80%, respectively). In those on monotherapy a renin-angiotensin system (RAS) blocker was the most commonly used drug class (62%) and use of other drug classes was only approximately 10%. In those on 2+ therapy, a RAS blocker was also the most common class (80%), followed by a diuretic (67%). In diabetics with hypertension 46 and 54% were on monotherapy vs. 2+ drug therapy with significantly higher control rates on monotherapy (90 vs. 46%). RAS blocker was also the most common drug class (85 and 80%, respectively), but in those on 2+ drugs only 45% were on a diuretic. Control rates did not differ by type of drug treatment in the overall hypertensive population and those with a comorbidity, but were low in diabetics on 2+ therapy and particularly in those on a calcium channel blocker (CCB) or diuretic. CONCLUSIONS: High treatment and control rates of hypertension in Ontario are associated with high utilization of RAS blockers. Diabetics on 2+ therapy are the least effectively controlled, possibly reflecting the limited use of diuretics.
BACKGROUND: The Ontario Blood Pressure (ON-BP) survey reported high treatment and control rates for hypertension in the province of Ontario, Canada, in a survey performed in 2006. This study examined patterns of utilization of antihypertensive drug classes and their impact on blood pressure (BP) control. METHODS: Cross-sectional, population-based survey of adults, 20-79 years of age (population 7,996,653). Responses are weighted to the Ontario hypertensive population of 1,498,045. RESULTS: Of all hypertensives, 51 and 49% were on monotherapy vs. 2+ drug therapy with similar control rates (86 vs. 80%, respectively). In those on monotherapy a renin-angiotensin system (RAS) blocker was the most commonly used drug class (62%) and use of other drug classes was only approximately 10%. In those on 2+ therapy, a RAS blocker was also the most common class (80%), followed by a diuretic (67%). In diabetics with hypertension 46 and 54% were on monotherapy vs. 2+ drug therapy with significantly higher control rates on monotherapy (90 vs. 46%). RAS blocker was also the most common drug class (85 and 80%, respectively), but in those on 2+ drugs only 45% were on a diuretic. Control rates did not differ by type of drug treatment in the overall hypertensive population and those with a comorbidity, but were low in diabetics on 2+ therapy and particularly in those on a calcium channel blocker (CCB) or diuretic. CONCLUSIONS: High treatment and control rates of hypertension in Ontario are associated with high utilization of RAS blockers. Diabetics on 2+ therapy are the least effectively controlled, possibly reflecting the limited use of diuretics.
Authors: Suzanne Murray; Patrice Lazure; Sara Schroter; Philipp J Leuschner; Peter Posel; Thomas Kellner; Richard D Jenkins Journal: BMC Fam Pract Date: 2011-05-11 Impact factor: 2.497
Authors: Scott W Klarenbach; Finlay A McAlister; Helen Johansen; Karen Tu; Maureen Hazel; Robin Walker; Kelly B Zarnke; Norman R C Campbell Journal: Can J Cardiol Date: 2010-05 Impact factor: 5.223
Authors: Norm R C Campbell; Richard E Gilbert; Lawrence A Leiter; Pierre Larochelle; Sheldon Tobe; Arun Chockalingam; Richard Ward; Dorothy Morris; Ross T Tsuyuki; Stewart B Harris Journal: Can Fam Physician Date: 2011-09 Impact factor: 3.275
Authors: Norman R C Campbell; Lawrence A Leiter; Pierre Larochelle; Sheldon Tobe; Arun Chockalingam; Richard Ward; Dorothy Morris; Ross Tsuyuki Journal: Can J Cardiol Date: 2009-05 Impact factor: 5.223